依那西普治疗供者干细胞移植后特发性肺炎综合征年轻患者
该数据集来自 clinicaltrials.gov,聚焦于接受供者干细胞移植后发生特发性肺炎综合征的年轻患者,使用依那西普进行干预

基本信息
资源简介
依那西普治疗供者干细胞移植后特发性肺炎综合征年轻患者
该数据集来自 clinicaltrials.gov,聚焦于接受供者干细胞移植后发生特发性肺炎综合征的年轻患者,使用依那西普进行干预。覆盖的疾病包括加速期和急变期慢性髓性白血病、缓解期儿童急性淋巴细胞白血病和急性髓性白血病、儿童慢性髓性白血病、儿童骨髓增生异常综合征及新发骨髓增生异常综合征。主要目标为评估第28天生存及完全停用补充氧气的应答率,次要目标包括第56天生存率、总生存分布及肺部应答。可用于血液肿瘤移植后并发症的疗效预测与生存分析(来源 clinicaltrials.gov)。
【数据内容】
源站描述(机器翻译,仅供参考):条件:加速期慢性髓性白血病、急变期慢性髓性白血病、缓解期儿童急性淋巴细胞白血病、缓解期儿童急性髓性白血病、儿童慢性髓性白血病、儿童骨髓增生异常综合征、慢性期慢性髓性白血病、新发骨髓增生异常综合征。主要目标:I. 确定在接受异基因干细胞移植后发生急性非感染性肺功能障碍(特发性肺炎综合征[IPS])的儿科患者中,接受依那西普治疗后的应答率,定义为第28天生存且完全停用补充氧气。次要目标:I. 估计接受该药物治疗的患者的第56天生存率。II. 确定接受该药物治疗的患者的总生存分布。III. 确定肺部应答,a
【主题与分类】
主题标签:Childhood Chronic Myelogenous Leukemia、Childhood Myelodysplastic Syndromes、de Novo Myelodysplastic Syndromes、Disseminated Neuroblastoma、Juvenile Myelomonocytic Leukemia、Pulmonary Complications、Recurrent Childhood Large Cell Lymphoma、Recurrent Childhood Rhabdomyosarcoma、Recurrent Neuroblastoma、Relapsing Chronic Myelogenous Leukemia。本站分类:肿瘤/白血病。
【获取与许可】
源站页面:https://clinicaltrials.gov/study/NCT00309907
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载,适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档,适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务(收技术服务费,非数据销售)
暂未开放当前数据集主要来源为 Kaggle 公开托管,完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取
源站:https://clinicaltrials.gov/study/NCT00309907
标准获取流程:
- 访问源站链接,注册/登录账号;
- 进入数据集详情页,按页面指引申请权限或直接下载;
- 部分平台提供 SDK,例如:
- OpenDataLab:
pip install openxlab后openxlab.dataset.get(...) - ModelScope:
pip install modelscope后modelscope download - 天池: 登录后页面提供直链下载
以源站「数据下载/使用文档」页面为准。
- OpenDataLab:
数据说明
Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes. PRIMARY OBJECTIVES: I. Determine the response rate, defined as survival and complete discontinuation of supplemental oxygen at day 28, in pediatric patients with acute noninfectious pulmonary dysfunction (idiopathic pneumonia syndrome [IPS]) after undergoing allogeneic stem cell transplantation treated with etanercept. SECONDARY OBJECTIVES: I. Estimate the day 56 survival rate in patients treated with this drug. II. Determine the overall survival distribution in patients treated with this drug. III. Determine the pulmonary response, as defined as the time to discontinuation of supplemental oxygen, in patients treated with this drug. IV. Evaluate the toxicity of etanercept therapy in patients with IPS. V. Evaluate levels of pro-inflammatory cytokines, in both bronchoalveolar lavage (BAL) fluid and serum, in patients with IPS. VI. Describe C-reactive protein (CRP) levels at baseline, day 7, 14, 21, and 28 and their association with response in patients with IPS. OUTLINE: This is an open-label, nonrandomized, multicenter study. Patients receive etanercept IV over 30 minutes on day 0 and subcutaneously on days 3, 7, 10, 14, 17, 21, and 24. Treatment continues in the absence of an infectious pathogen, disease progression, or unacceptable toxicity. Patients also receive methylprednisolone (or corticosteroid equivalent) IV on days 0-2 and then orally with a taper until day 56. After completion of study treatment, patients are followed periodically for 5 years.
数据加载示例(图像类)
from PIL import Image
import glob, os
files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)
# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path) # 要求 子目录=类别
目录组织与标注格式以源站说明和下载后实际文件为准。
数据缺失?
依托陕西、四川两大基地,我们与超过十家三甲医院建立直接合作关系,覆盖合规授权、采集治理、专业标注、数据交付的全流程,为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务?立即联系我们获取专业方案。




